Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-α, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: Final results of cancer biotherapy research group 94-11

Cancer Biotherapy and Radiopharmaceuticals

Volumn 15, Issue 5, 2000, Pages 487-494

  Dillman, R O ^a   Soori, G ^b   Wiemann, M C ^c   Schulof, R ^d   Dobbs, T W ^e   Ruben, R H ^d   Depriest, C B ^f   Church, C ^f  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b Alegent Bergan Mercy Medical Center   (Canada)

^c St Vincent Medical Center   (United States)

^d Denver CO ^*  (United States)

^e Baptist Regional Cancer Center   (United States)

^f Cancer Biotherapy Research Group   (United States)

Author keywords

Biotherapy; Chemotherapy; Interferon ; Interleukin 2; Melanoma

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN; TAMOXIFEN CITRATE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; FATIGUE; FEMALE; FEVER; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; MELANOMA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TUMOR GROWTH;

EID: 0033711663     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2000.15.487     Document Type: Article

References (32)

1. The emerging epidemic of melanoma and squamous cell skin cancer
2. Current therapy for cutaneous melanoma
3. Combination chemotherapy with Cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma
4. Combination chemo/hormonal therapy in the treatment of malignant melanoma
5. The Dartmouth regimen: Gone or going strong?
6. Interferon-a and chemohormonal therapy for patients with advanced melanoma: Final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program
7. Combination biotherapy utilizing interleukin-2 and alpha interferon inpatients with advanced cancer: A National Biotherapy Study Group trial
8. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer
9. Interferon-α and interleukin-2 in the treatment of metastatic melanoma: Comparison of two phase II trials
10. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a inpatients with advanced melanoma
11. Sequential chemoimmunotherapy with Cisplatin, interleukin-2 and interferon alfa-2a for metastatic melanoma
12. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma
13. High dose IL-2 therapy alone results in long-term durable complete responses in patients with metastatic melanoma
14. Long-term survival after continuous infusion interleukin-2
15. The clinical experience with interleukin-2 in cancer therapy
16. Why event-free survival is better than tumor response or other measures of survival as an endpoint in cancer trials
17. Nonparametric estimation from incomplete observations
18. Development of a biochemotherapy regimen with concurrent administration of Cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
19. Rationale for Intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone inpatients with metastatic melanoma
20. Experience with high-dose continuous infusion interleukin-2 in the treatment of 788 cancer patients
21. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: A phase II trial of the Cancer Biotherapy Research Group (formerly the National Biotherapy Study Group)
22. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: A National Biotherapy Study Group trial
23. The importance oftamoxifen to a cisplatincontaining regimen in the treatment of metastatic melanoma
24. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and Cisplatin with and without tamoxifen in patients with metastatic melanoma
25. Phase II study of carmustine, dacarbazine, Cisplatin, and tamoxifen in advanced melanoma: A Southwest Oncology Group Study
26. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine inpatients with metastatic melanoma
27. Randomized phase Ill study of temazolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
28. Sequential chemoimmunotherapy in the treatment of metastatic melanoma
29. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma
30. Interferon alfa-2a and interleukin-2 with or without Cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group
31. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b
32. What to do with IL-2?